Sorafenib for the Treatment of Advanced Renal Cell Carcinoma
Robert C. Kane(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Patricia Garvey(United States Food and Drug Administration), Chengyi Liang(United States Food and Drug Administration), Robert Justice(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Josephine M. Jee(United States Food and Drug Administration), Ann T. Farrell(Center for Drug Evaluation and Research), Gene M. Williams(United States Food and Drug Administration), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Haleh Saber(United States Food and Drug Administration), Nallaperumal Chidambaram, Brian Booth, David E. Morse(United States Food and Drug Administration)
Cited by 466
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k